Rheumatology

Disease Analysis: Rheumatoid Arthritis

Market Spotlight: Psoriatic Arthritis

This Market Spotlight report covers the psoriatic arthritis market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

September 9, 2020

Market Spotlight: Gout

This Market Spotlight report covers the Gout market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, a 10-year disease prevalence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

September 9, 2020

Market Spotlight: Sjögren’s Syndrome

This Market Spotlight report covers the Sjögren’s syndrome market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.

September 3, 2020

Market Spotlight: Axial Spondyloarthritis (axSpA)

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

September 3, 2020

Market Spotlight: Osteoarthritis and Osteoarthritis Pain

This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

August 21, 2020

Rheumatoid Arthritis Payer Interview – Pennsylvania, US

A US payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

August 22, 2019

Rheumatoid Arthritis Payer Interview – UK

A UK payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

August 22, 2019

Rheumatoid Arthritis KOL Interview – California, US

A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

Rheumatoid Arthritis KOL Interview – UK

A UK-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

Rheumatoid Arthritis KOL Interview – New Jersey, US

A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

Rheumatoid Arthritis KOL Interview – New Jersey, US

A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.